Home
About Us
Company Overview
Mission
Leadship
Milestones
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
EN
中文
EN
Home
About Us
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
News
News
News
07-11
2023
Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism
2023-07-11
06-23
2023
Sciwind Biosciences to Highlight Positive Clinical Data for GLP-1 Peptide Agonist Ecnoglutide (XW003) at the American Diabetes Association (ADA) 83rd Annual Conference
2023-06-23
01-30
2023
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China
2023-01-30
10-27
2022
Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity
2022-10-27
10-09
2022
Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes
2022-10-09
09-26
2022
Sciwind Biosciences and SynerK Enter into Research Partnership to Discover and Develop Novel siRNA Therapeutics
2022-09-26
<
1
2
3
4
5
>
